Medical devices have progressed from their initial bulky forms to smart devices. However, their rigidity hampers their seamless integration into everyday life. The fields of stretchable, textile, and flexible electronics are emerging research areas with the potential to drive significant technological progress. This research presents a laboratory-based technique to produce highly sensitive and flexible biosensors for detecting the chikungunya virus. These biosensors are based on 0D nanomaterials and demonstrate significant advancements in voltammetry. The electrochemical platform was created utilizing the stencil printing (StPE) technique. Adapting the biosensor setup involved the selection of aptamer as the biorecognition element bound with silver nanoparticles (AgNPs). This biosensor was employed in the voltammetric identification of the Chikungunya virus antigen (CHIKV-Ag) within a solution containing 0.5 mM potassium ferro/ferri cyanide, a redox pair. The biosensor was employed to evaluate CHIKV-Ag within a human serum sample. It demonstrated a linear detection span ranging from 0.1 ng/mL to 1 μg/mL, with a detection limit of 0.1 ng/mL for CHIKV-Ag. The proposed approach, due to its flexibility in production and the electrocatalytic attributes displayed by the zero-dimensional nanostructure, presents innovative opportunities for cost-effective and tailored aptamer-based bioelectronics, thereby broadening the scope of this domain.

Lung cancer remains one of the main causes of cancer-related death globally and a significant global health concern. There is an urgent need for safer and more effective therapeutic alternatives despite notable progress in therapy; issues such as drug resistance, side effects, metastasis, and recurrence still affect patient outcome and quality of life. The aim of this review is to examine recent developments in the application of herbal-drug-loaded nanoparticles as a new strategy for treating lung cancer. A thorough examination of different drug delivery systems based on nanoparticles is provided, highlighting their function in improving the solubility, bioavailability, and targeted delivery of herbal compounds. In addition, the review evaluates the biomarkers used for targeted therapy and examines how new personalised treatment approaches like wearable electronic patches, robotics-assisted interventions, smartphone-enabled therapies, AI-driven diagnostics, and lung-on-a-chip technologies can be integrated to improve the accuracy and effectiveness of lung cancer treatment. In conclusion, the combination of personalised medicine and nanotechnology may lead to revolutionary changes in lung cancer treatment in the future.